Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19061465 | FORMULATIONS OF BENDAMUSTINE | February 2025 | May 2025 | Allow | 3 | 1 | 0 | No | No |
| 19061632 | BISPECIFIC STEALTH LIPID NANOPARTICLE COMPOSITIONS FOR CELL TARGETING | February 2025 | June 2025 | Allow | 4 | 0 | 0 | No | No |
| 19060293 | URSOLIC ACID MORPHOLINE SALT | February 2025 | June 2025 | Allow | 3 | 1 | 0 | Yes | No |
| 19025220 | GELS FOR INSULIN DELIVERY | January 2025 | April 2025 | Allow | 3 | 1 | 0 | No | No |
| 19025668 | METHODS AND COMPOSITIONS FOR TESTOSTERONE PRODUCTION | January 2025 | April 2025 | Allow | 3 | 1 | 0 | Yes | No |
| 19022909 | SLEEP-IMPROVING COMPOSITIONS AND METHODS OF USE | January 2025 | March 2025 | Allow | 2 | 0 | 0 | Yes | No |
| 19022531 | LEVODOPA DOSING REGIMEN | January 2025 | April 2025 | Allow | 3 | 0 | 0 | Yes | No |
| 19021929 | LEVODOPA DOSING REGIMEN | January 2025 | June 2025 | Allow | 5 | 1 | 0 | No | No |
| 19022122 | LEVODOPA DOSING REGIMEN | January 2025 | April 2025 | Allow | 3 | 1 | 0 | No | No |
| 19021696 | LEVODOPA DOSING REGIMEN | January 2025 | June 2025 | Allow | 5 | 1 | 0 | No | No |
| 19013003 | PHARMACEUTICAL SOLUTION OF AMLODIPINE | January 2025 | June 2025 | Allow | 5 | 1 | 0 | No | No |
| 19005284 | DRUG POWDERIZATION WITHIN VIALS | December 2024 | June 2025 | Allow | 6 | 1 | 0 | No | No |
| 19004850 | MUCO-ADHESIVE, CONTROLLED RELEASE FORMULATION OF LEVODOPA AND/OR ESTERS OF LEVODOPA AND USES THEREOF | December 2024 | June 2025 | Allow | 6 | 1 | 0 | No | No |
| 19004480 | IMMUNOMODULATORY HYDROGEL AND PREPARATION METHOD THEREOF | December 2024 | June 2025 | Allow | 6 | 1 | 0 | No | No |
| 18985130 | MULTIFUNCTIONAL MICROBIAL AGENT AND APPLICATIONS THEREOF | December 2024 | March 2025 | Allow | 3 | 0 | 0 | No | No |
| 18983625 | GADOLINIUM CHELATE COMPOUNDS FOR USE IN MAGNETIC RESONANCE IMAGING | December 2024 | June 2025 | Allow | 6 | 1 | 0 | No | No |
| 18979375 | Coffee Bean Compositions Comprising Paraxanthine and Methods for Their Production | December 2024 | February 2025 | Allow | 2 | 0 | 0 | No | No |
| 18978361 | Liquid supramolecular self-recognition system of low-pH azelaic acid, and preparation method therefor and application thereof | December 2024 | April 2025 | Allow | 4 | 1 | 1 | Yes | No |
| 18977228 | Ribociclib Tablet | December 2024 | June 2025 | Allow | 7 | 3 | 0 | No | No |
| 18977541 | COMPOSITIONS AND COMPOUNDS CONTAINNG BETA-HYDROXYBUTYRATE AND ONE OR MORE AMINO ACIDS | December 2024 | March 2025 | Allow | 3 | 0 | 0 | Yes | No |
| 18977838 | LEONURINE NANOCOMPOSITE HYDROGEL AND PREPARATION METHODS AND APPLICATIONS THEREOF | December 2024 | April 2025 | Allow | 4 | 1 | 0 | No | No |
| 18975647 | Herbicidal compositions comprising 2,4-D | December 2024 | June 2025 | Allow | 6 | 1 | 0 | Yes | No |
| 18975144 | MUCO-ADHESIVE, CONTROLLED RELEASE FORMULATION OF LEVODOPA AND/OR ESTERS OF LEVODOPA AND USES THEREOF | December 2024 | February 2025 | Allow | 2 | 1 | 0 | No | No |
| 18871962 | 1,4-BIS-(2-HYDROXY-BENZYL)-1,4,7-TRIAZACYCLONONANE DERIVATIVES AND SIMILAR COMPOUNDS AS LIGANDS IN IRON(III) COMPLEXES FOR USE AS MRI CONTRAST AGENTS | December 2024 | June 2025 | Allow | 6 | 0 | 1 | No | No |
| 18967829 | Formulations of Enzalutamide | December 2024 | May 2025 | Allow | 6 | 1 | 0 | Yes | No |
| 18962073 | BURN WOUND TREATMENT | November 2024 | April 2025 | Allow | 5 | 1 | 1 | No | No |
| 18957404 | MANUFACTURING OF BUPIVACAINE MULTIVESICULAR LIPOSOMES | November 2024 | April 2025 | Allow | 5 | 1 | 0 | Yes | No |
| 18953603 | TAMPER RESISTANT DOSAGE FORMS | November 2024 | February 2025 | Allow | 3 | 1 | 0 | No | No |
| 18951096 | Lip Balm Containing Caffeine, Nicotine or Testosterone | November 2024 | March 2025 | Allow | 4 | 1 | 0 | No | No |
| 18950649 | BIOTHERAPY FOR VIRAL INFECTIONS USING BIOPOLYMER BASED MICRO/NANOGELS | November 2024 | February 2025 | Allow | 3 | 1 | 0 | No | No |
| 18950997 | CANCER TREATMENT METHOD WITH NANOCOMPOSITE | November 2024 | January 2025 | Allow | 2 | 1 | 0 | No | No |
| 18948050 | CRYSTALLINE FORM OF TRIETHYLENETETRAMINE TETRAHYDROCHLORIDE AND ITS PHARMACEUTICAL USE | November 2024 | March 2025 | Allow | 4 | 1 | 0 | No | No |
| 18947430 | SODIUM THIOSULFATE-CONTAINING PHARMACEUTICAL COMPOSITIONS | November 2024 | April 2025 | Allow | 5 | 1 | 0 | Yes | No |
| 18944456 | AQUEOUS SUSPENSION SUITABLE FOR ORAL ADMINISTRATION | November 2024 | June 2025 | Allow | 7 | 1 | 0 | Yes | No |
| 18934978 | PHARMACEUTICAL COMPOSITIONS | November 2024 | April 2025 | Allow | 6 | 1 | 0 | Yes | No |
| 18928649 | OPIOID FORMULATIONS | October 2024 | March 2025 | Allow | 4 | 1 | 0 | No | No |
| 18926566 | COENZYME Q10 COMPOSITION, AND PREPARATION METHOD AND APPLICATION THEREOF IN CARDIO-PROTECTION | October 2024 | January 2025 | Allow | 3 | 0 | 0 | No | No |
| 18927047 | Stable, concentrated radionuclide complex solutions | October 2024 | May 2025 | Allow | 7 | 0 | 1 | Yes | No |
| 18927034 | Stable, concentrated radionuclide complex solutions | October 2024 | February 2025 | Abandon | 4 | 0 | 0 | No | No |
| 18923418 | CENTANAFADINE PHARMACEUTICAL FORMULATIONS, AND METHODS OF MAKING AND USING SAME | October 2024 | March 2025 | Allow | 5 | 1 | 0 | Yes | No |
| 18923620 | ANTI-AGING PREPARATION FOR SKIN AND APPLICATION THEREOF | October 2024 | January 2025 | Allow | 3 | 1 | 0 | No | No |
| 18921291 | PHARMACEUTICAL COMPOSITIONS COMPRISING BUPROPION AND CYSTEINE | October 2024 | March 2025 | Allow | 5 | 1 | 0 | Yes | No |
| 18917080 | PHARMACEUTICAL FORMULATIONS COMPRISING NALTREXONE AND/OR BUPROPION | October 2024 | April 2025 | Allow | 6 | 1 | 1 | Yes | No |
| 18915867 | HYDROXYAPATITE-ENCLOSED ZINC PHOSPHATE NANOCOMPOSITE | October 2024 | December 2024 | Allow | 2 | 0 | 0 | Yes | No |
| 18915144 | READY-TO-USE SODIUM PHOSPHATES INJECTION | October 2024 | February 2025 | Allow | 4 | 1 | 0 | Yes | No |
| 18913776 | DOUBLE-NETWORK VERSATILE HYDROGEL WITH ANTIBACTERIAL AND DRUG SEQUENTIAL RELEASE CAPABILITIES | October 2024 | February 2025 | Allow | 5 | 1 | 0 | No | No |
| 18911732 | MUCO-ADHESIVE, CONTROLLED RELEASE FORMULATION OF LEVODOPA AND/OR ESTERS OF LEVODOPA AND USES THEREOF | October 2024 | December 2024 | Allow | 2 | 1 | 0 | No | No |
| 18910781 | URSOLIC ACID MORPHOLINE AND DIETHANOLAMINE SALTS | October 2024 | November 2024 | Allow | 1 | 0 | 0 | Yes | No |
| 18911121 | METHOD FOR TREATING ENDOMETRIOSIS AND PROVIDING EFFECTIVE CONTRACEPTION | October 2024 | May 2025 | Allow | 7 | 1 | 1 | Yes | No |
| 18910243 | SKINCARE COOLING PRODUCT, METHOD OF MAKING, AND METHOD OF USING THE SAME | October 2024 | April 2025 | Allow | 6 | 1 | 1 | Yes | No |
| 18909414 | POLYMERIC ANTI-MICROBIAL FILM | October 2024 | December 2024 | Allow | 2 | 0 | 0 | No | No |
| 18908215 | Termite Trailing and Recruitment Product and Process | October 2024 | April 2025 | Allow | 6 | 1 | 0 | Yes | No |
| 18906740 | METHOD OF DELIVERY OF DNA OR RNA CARGO USING UNSHIELDED LIPID NANOPARTICLES AND COMPOSITIONS THEREOF | October 2024 | March 2025 | Allow | 5 | 1 | 0 | No | No |
| 18905806 | FORMULATION OF EAR DROPS AND METHODS FOR DELIVERY THEREOF FOR TREATING UPPER RESPIRATORY INFECTIONS | October 2024 | April 2025 | Allow | 6 | 1 | 1 | Yes | No |
| 18904951 | Constrained Ionizable Cationic Lipids and Lipid Nanoparticles | October 2024 | May 2025 | Allow | 8 | 0 | 1 | No | No |
| 18897019 | Pathogenic Affinity Pathway of Infectious or Parasitic Organisms for Nanogram and Picogram Dosimetry Prophylaxis or Cure | September 2024 | December 2024 | Allow | 3 | 0 | 0 | Yes | No |
| 18897657 | OPHTHALMIC FORMULATIONS AND METHODS OF USE | September 2024 | January 2025 | Allow | 4 | 1 | 0 | No | No |
| 18898561 | ANTIBACTERIAL CONDUCTIVE SELF-HEALING HYDROGEL | September 2024 | December 2024 | Allow | 2 | 0 | 0 | No | No |
| 18896954 | 3D PRINTED BONE DEFECT REPAIR SCAFFOLD LOADED WITH EXTRACELLULAR MATRIX OF MESENCHYMAL STEM CELLS AND PREPARATION METHOD THEREOF | September 2024 | May 2025 | Abandon | 8 | 1 | 0 | No | No |
| 18894811 | THERAPEUTIC METHODS USING BUPROPION HYDROBROMIDE TO TREAT MAJOR DEPRESSIVE DISORDER | September 2024 | March 2025 | Allow | 6 | 1 | 0 | No | No |
| 18893805 | TREATMENT OF DIABETIC RETINOPATHY WITH OPHTHALMIC COMPOSITIONS | September 2024 | April 2025 | Allow | 6 | 1 | 0 | No | No |
| 18893796 | STABILIZED OPHTHALMIC DEXAMETHASONE COMPOSITIONS | September 2024 | May 2025 | Allow | 8 | 1 | 0 | No | No |
| 18893790 | TREATMENT OF OCULAR INFLAMMATION FOLLOWING OCULAR SURGERY | September 2024 | May 2025 | Allow | 7 | 1 | 0 | Yes | No |
| 18893806 | PH STABILIZED OPHTHALMIC DEXAMETHASONE COMPOSITIONS | September 2024 | May 2025 | Allow | 8 | 1 | 0 | Yes | No |
| 18893810 | PH STABILIZED OPHTHALMIC COMPOSITIONS | September 2024 | May 2025 | Allow | 8 | 1 | 0 | No | No |
| 18893280 | COMPOSITIONS AND METHODS FOR DELIVERY OF RNA | September 2024 | June 2025 | Allow | 9 | 1 | 0 | No | No |
| 18891739 | ION CHANNEL PROSTHETIC COMPOSITIONS COMPRISING LIPID-COATED CRYSTALS OF AMPHOTERICIN B | September 2024 | May 2025 | Allow | 8 | 2 | 1 | No | No |
| 18848678 | BIOACTIVE GRANULAR HYDROGEL SCAFFOLDS AND USE THEREOF | September 2024 | April 2025 | Allow | 7 | 2 | 0 | Yes | No |
| 18889055 | MODIFIED RELEASE GAMMA- HYDROXYBUTYRATE FORMULATIONS HAVING IMPROVED PHARMACOKINETICS | September 2024 | February 2025 | Allow | 5 | 0 | 0 | No | No |
| 18889023 | MODIFIED RELEASE GAMMA- HYDROXYBUTYRATE FORMULATIONS HAVING IMPROVED PHARMACOKINETICS | September 2024 | December 2024 | Allow | 3 | 0 | 0 | Yes | No |
| 18889070 | MODIFIED RELEASE GAMMA- HYDROXYBUTYRATE FORMULATIONS HAVING IMPROVED PHARMACOKINETICS | September 2024 | January 2025 | Allow | 4 | 0 | 0 | No | No |
| 18886244 | Oral Care Compositions Comprising Monodentate And Polydentate Ligand | September 2024 | June 2025 | Allow | 9 | 2 | 0 | Yes | No |
| 18829557 | NOVEL LIPID NANOPARTICLE COMPOSITIONS AND USES THEREOF | September 2024 | April 2025 | Allow | 7 | 1 | 0 | Yes | No |
| 18830440 | COMPOSITION AND METHOD FOR REDUCING RISK OF HYPOCALCEMIA IN PERIPARTURIENT RUMINANT ANIMALS | September 2024 | March 2025 | Allow | 6 | 2 | 0 | Yes | No |
| 18823575 | LEVODOPA DOSING REGIMEN | September 2024 | April 2025 | Allow | 7 | 1 | 0 | No | No |
| 18823153 | LEVODOPA DOSING REGIMEN | September 2024 | December 2024 | Allow | 3 | 1 | 0 | No | No |
| 18823274 | PHARMACEUTICAL COMPOSITION | September 2024 | April 2025 | Allow | 7 | 1 | 0 | No | No |
| 18823257 | PHARMACEUTICAL COMPOSITION | September 2024 | March 2025 | Allow | 6 | 1 | 0 | No | No |
| 18842405 | ORAL CARE PRODUCT | August 2024 | February 2025 | Allow | 5 | 0 | 0 | No | No |
| 18817743 | LEVODOPA DOSING REGIMEN | August 2024 | February 2025 | Allow | 6 | 1 | 0 | Yes | No |
| 18818363 | TOPICAL COMPOSITION FOR IMPROVED HEALING OF OPEN WOUNDS | August 2024 | April 2025 | Allow | 7 | 1 | 0 | Yes | No |
| 18816200 | PARTICLES COMPRISING A THERAPEUTIC OR DIAGNOSTIC AGENT AND SUSPENSIONS AND METHODS OF USE THEREOF | August 2024 | January 2025 | Allow | 5 | 1 | 0 | No | No |
| 18841788 | DOUBLE-CROSSLINKED FIBRIN GEL, RAW MATERIAL COMPOSITION AND KIT THEREOF, AND APPLICATION THEREOF | August 2024 | June 2025 | Allow | 9 | 1 | 0 | No | No |
| 18811352 | PHARMACEUTICAL COMPOSITION WITH NANOPARTICLE-BASED DRUG DELIVERY COMBINED WITH NON-INVASIVE RADIOGRAPHIC MONITORING MODEL | August 2024 | February 2025 | Allow | 6 | 1 | 0 | No | No |
| 18811158 | METHODS FOR FIXING HAIR AND SKIN | August 2024 | November 2024 | Allow | 3 | 1 | 0 | No | No |
| 18808392 | TREATMENT OF IMMUNOSUPPRESSED SUBJECTS | August 2024 | March 2025 | Allow | 7 | 1 | 0 | No | No |
| 18806627 | Technology for improving properties of lipid nanoparticles using lipids in which cis-unsaturated bonds are substiuted with a silicon atom | August 2024 | March 2025 | Allow | 7 | 1 | 0 | No | No |
| 18802458 | LEVODOPA DOSING REGIMEN | August 2024 | February 2025 | Allow | 6 | 1 | 0 | Yes | No |
| 18802151 | LEVODOPA DOSING REGIMEN | August 2024 | April 2025 | Allow | 8 | 2 | 0 | Yes | No |
| 18799983 | COMPOSITION AND METHOD FOR TREATING HEARING LOSS | August 2024 | April 2025 | Allow | 8 | 1 | 1 | Yes | No |
| 18797696 | Mycophenolate Oral Suspension | August 2024 | November 2024 | Allow | 3 | 1 | 0 | Yes | No |
| 18797717 | Mycophenolate Oral Suspension | August 2024 | December 2024 | Allow | 4 | 1 | 0 | No | No |
| 18795731 | COMPOSITIONS OF 1-(4-BROMO-5-(1-ETHYL-7-(METHYLAMINO)-2-OXO-1,2-DIHYDRO-1,6-NAPHTHYRIDIN-3-YL)-2-FLUOROPHEYL)-3-PHENYLUREA | August 2024 | October 2024 | Allow | 2 | 0 | 0 | Yes | No |
| 18795683 | COMPOSITIONS OF 1-(4-BROMO-5-(1-ETHYL-7-(METHYLAMINO)-2-OXO-1,2-DIHYDRO-1,6-NAPHTHYRIDIN-3-YL)-2-FLUOROPHEYL)-3-PHENYLUREA | August 2024 | October 2024 | Allow | 2 | 0 | 0 | Yes | No |
| 18795711 | COMPOSITIONS OF 1-(4-BROMO-5-(1-ETHYL-7-(METHYLAMINO)-2-OXO-1,2-DIHYDRO-1,6-NAPHTHYRIDIN-3-YL)-2-FLUOROPHEYL)-3-PHENYLUREA | August 2024 | October 2024 | Allow | 2 | 0 | 0 | Yes | No |
| 18795653 | Surfactin-Based Lipopeptide for mRNA Delivery | August 2024 | February 2025 | Allow | 6 | 1 | 0 | Yes | No |
| 18795667 | Surfactin-Based Lipopeptide for mRNA Delivery | August 2024 | February 2025 | Allow | 6 | 1 | 0 | No | No |
| 18794390 | ADAGRASIB SOLID PHARMACEUTICAL COMPOSITIONS | August 2024 | February 2025 | Allow | 6 | 2 | 0 | Yes | No |
| 18792849 | Methods of administering safe colon cleansing compositions | August 2024 | February 2025 | Allow | 7 | 1 | 0 | No | No |
| 18793091 | Herbicidal compositions comprising trifludimoxazin | August 2024 | September 2024 | Allow | 2 | 0 | 0 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for group 1610.
With a 27.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is in the bottom 25% across the USPTO, indicating that appeals face significant challenges here.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 20.8% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Group 1610 is part of Technology Center 1600. This group has examined 110,142 patent applications in our dataset, with an overall allowance rate of 48.5%. Applications typically reach final disposition in approximately 33 months.
Applications in Group 1610 receive an average of 2.30 office actions before reaching final disposition. The median prosecution time is 33 months.
This group-level data aggregates statistics across multiple art units. For more targeted prosecution strategies, review the individual art unit and examiner statistics within this group.
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.